FinTwit Review

I bookmarked this post in 2024. I don’t remember why. So let’s see what happened?

I am going to post a chart from the day of this tweet (or closest date I have.)

No judgment here. How a trade plays out depends very much on when a person enters and exits. I just want to see what the state was at the time and what happened.

AnaptysBio ($ANAB) a company name only Daffy Duck would love was trading at $22. And just tripped the channel. I would say going long was a much better trade. The event window was orange and the stock did go down in that window but once the stock was in the channel the play was to go long. It is currently trading at $62.

We played this in the channel in 2025.

Biomea Fusion ($BMEA) was trading at a very lucky price point of $8.88 and was far outside the channel. It is currently trading at $1.85. Short was the smart trade. There are actually two over lapping event windows. One green and one orange.

Cardiff Oncology ($CRDF) was trading at $3.81. It ran to $4.45 after this but as you can see was far outside the channel. Currently, trading at $1.67. Short was the smart trade.

Candel Therapeutics was trading at $5.33 and is still at $4.80. There really was no smart trade in this in 2024. It’s just flatlined. This was a really big win for us in 2023-2024.

CervoMed Inc ($CRVO) was trading at $12.84. Currently trading at $4.99. Another great play from the channel in 2023. Short was the right trade. The event window was orange.

Galectin Therapeutics was trading at $2.81. This stock did crash right after the original post. At the time the code could not classify the risk event. That’s why it was grey.

As the system gathered more data it was able to mark the event orange. There was a green event that caused the stock to start to squeeze. Which it did all the way to $6+. This was a very crowded retail short and it destroyed a lot of people.

Neumora Therapetics ($NMRA) did crash in that yellow event window.

Cassava Sciences ($SAVA) was a really crowded retail trade. Completely collapsed. This stock was never in the channel. In Abivax was in the channel before its move.

Sellas Life Sciences is one of the most promoted stocks in the sector and has been for many years. This stock right now is getting pumped and is an extremely crowded trade now. Since the tweet the stock is up 400% and is currently at $5.05.

Syros Pharmaceuticals ($SRYS) was in the channel. But this chart looks terrifying. This stock last traded at 0.0002.

So out of ten stocks, one went to zero ($SAVA is now $FLNA.) Three made 3x or more.

You can see almost all were in the channel before the post and the returns form the channel run far exceed the return on shorting after the move.

Remember, you could be the best at running the pick-and-roll and still look stupid trying to do so while playing Tennis.

We own ($NRMA) today. Though not as much as we did. It made 5x last year after falling through the channel and then rebounding. So was shorting the stock the right trade? Or was buying after the reaction the right trade? Well, making both trades would have been smart. But, that is very difficult if you have a psychological attachment to your decision.

That’s the lesson here. Don’t get attached to your ideas. Because, there might be more money to be made you miss while high-fiving yourself.

As always, if you think there are spelling errors update your dictionary to the latest version. Happy speculation!

— AJ

DISCLAIMER: DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Our website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Past performance is not indicative of future results. The material contained on this page is intended for informational purposes only. GravityAnalytica.com is wholly-owned by Gravity Analytica, LLC. Our website is not an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content of our website and/or newsletter is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained on our website is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. We reserve the right to buy or sell shares of any company mentioned on our website or in our newsletter at any time. We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.

The company or individuals affiliated may hold positions or may enter into, or exit, positions on any equities at any time. This website and materials found on this website, or in any communication, are meant for individuals of eighteen (18) years of age or older and are not suitable for younger audiences. Materials and information provided on this website and in any communications with or from Gravity Analytica LLC, it’s employees or affiliates, are for personal education use by subscribers and may be not be used in any regard in competition with this website or any other product or service offered by Gravity Analytica LLC. Past results do not predict future returns. IF YOU DO NOT AGREE WITH THE TERMS OF THIS DISCLAIMER, PLEASE EXIT THIS SITE IMMEDIATELY. PLEASE BE ADVISED THAT YOUR CONTINUED USE OF THIS SITE OR THE INFORMATION PROVIDED HEREIN SHALL INDICATE YOUR CONSENT AND AGREEMENT TO THESE TERMS.